Patent search ipc:"C07D211/98" Page 1

1.

发明申请
SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 有权

公开(公告)号：US20250066359A1

公开(公告)日：2025-02-27

申请号：US18724366

申请日：2022-12-27

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Jianhua SHEN , Xin XIE , Yanglong ZHANG , Tingting ZHAO , Fanghui HAN , Ying YUN

IPC: C07D471/10 , A61K31/397 , A61K31/407 , A61K31/437 , A61K31/438 , A61K31/444 , A61K31/4523 , A61K31/495 , A61K31/496 , A61K31/5386 , A61K45/06 , A61P1/16 , A61P3/10 , C07D205/12 , C07D211/96 , C07D211/98 , C07D221/20 , C07D295/26 , C07D401/04 , C07D471/04 , C07D487/10 , C07D498/10

Abstract: Provided are a class of compounds which have a structure as shown in the following general formula (I) and are used as somatostatin receptor subtype 5 (SSTR5) antagonists, and a pharmaceutical composition and the use thereof. The compounds have good SSTR5 antagonistic activities, and can be used for preparing drugs for treating related diseases mediated by SSTR5.

2.

发明公开
ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20230159441A1

公开(公告)日：2023-05-25

申请号：US17955270

申请日：2022-09-28

Applicant: Ensysce Biosciences Inc.

Inventor： Lynn Kirkpatrick

IPC: C07C279/12 , C07D207/50 , C07D211/98 , C07D265/30 , C07D207/09 , A61K45/06

CPC classification number: C07C279/12 , C07D207/50 , C07D211/98 , C07D265/30 , C07D207/09 , A61K45/06

Abstract: The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, and an optional enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of methadone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

3.

发明申请
INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF 有权

公开(公告)号：US20230080054A1

公开(公告)日：2023-03-16

申请号：US17580652

申请日：2022-01-21

Applicant: ILDONG PHARMACEUTICAL CO., LTD.

Inventor： Jinah JEONG , Hyunjung KWAK , Gunhee KIM , Jeongeun KIM , Sanghwan LEE , Seolhee LEE , Jinhee LEE , Jihye CHOI , Hongchul YOON , Joontae PARK , Kyungmi AN , Jungwoo LEE , Eunjung LEE

IPC: C07D405/12 , C07D307/52 , C07D405/14 , C07D237/20 , C07D401/12 , C07D403/12 , C07D409/12 , C07C237/30 , C07D241/20 , C07D239/42 , C07D413/14 , C07D409/14 , C07D471/08 , C07D213/74 , C07D417/12 , C07D271/07 , C07D213/38 , C07D239/26 , C07D241/12 , C07D211/98

Abstract: The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.

4.

发明申请
METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C 有权

公开(公告)号：US20220024871A1

公开(公告)日：2022-01-27

申请号：US17203266

申请日：2021-03-16

Applicant: ACADIA Pharmaceuticals Inc.

Inventor： Marlon Carlos , Sagun Tandel , Roger Olsson , Mikael Hillgren , Matthew J. Fleming , Andreas Philipp Boudier , Beat T. Weber

IPC: C07D211/98

Abstract: Disclosed herein are methods for obtaining N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N-(4-(2-methylpropyloxy)phenylmethyl) carbamide (pimavanserin) comprising the step of contacting an intermediate according to Formula (A) or a salt thereof, with an intermediate Formula B, or a salt thereof, to produce pimavanserin or a salt thereof wherein Y is —ORi or —NR2aR2b; R3 is hydrogen or substituted or unsubstituted heteroalicyclyl, R4 is substituted or unsubstituted aralkyl; X is —OR22 or —NR23R24; (wherein R22 is hydrogen or substituted or unsubstituted C1-6alkyl and one of R23 and R24 is hydrogen and the other is hydrogen or N-methylpiperidin-4-yl); and R21 is —OCH2CH(CH3)2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

5.

发明授权
Method for preparing pimavanserin and tartrate thereof by using triphosgene 有权

公开(公告)号：US10934257B2

公开(公告)日：2021-03-02

申请号：US16764315

申请日：2019-07-19

Applicant: Livzon New North River Pharmaceutical Co., Ltd.

Inventor： Biao Wang , Qiao Jiang , Bingbing Li , Murong Peng , Weijian Xie

IPC: C07D211/98

Abstract: The present disclosure discloses a method for safely preparing pimavanserin and tartrate thereof by using triphosgene. The synthesis route includes: Raw materials used in the method of the present disclosure are safe and inexpensive, thereby effectively reducing the production costs. The method of the present disclosure has mild reaction conditions, and avoids using phosgene, which is highly toxic and difficult to handle is avoided. Thus, the method is readily implemented industrially.

6.

发明授权
GLP-1 receptor modulators 有权

公开(公告)号：US10034886B2

公开(公告)日：2018-07-31

申请号：US15711858

申请日：2017-09-21

Applicant: Celgene International II SÀRL

Inventor： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs , Daniel Glynn , Mark Mills

IPC: A61K31/506 , C07D403/10 , A61K31/551 , A61K31/4725 , A61K31/495 , A61K31/4545 , A61K31/454 , A61K31/4468 , A61K31/4439 , A61K31/445 , A61K31/44 , A61K31/433 , A61K31/4245 , A61K31/426 , A61K31/421 , A61K31/4178 , C07D495/04 , C07D471/04 , A61K31/402 , C07D417/12 , C07D413/12 , C07D413/04 , C07D409/14 , C07D409/12 , C07D407/12 , C07D405/12 , C07D403/12 , C07D403/04 , C07D401/12 , C07D401/06 , C07D401/04 , C07D295/135 , C07D295/084 , C07D285/12 , C07D285/08 , C07D277/30 , C07D271/107 , C07D271/06 , C07D263/32 , C07D253/065 , C07D253/06 , C07D243/08 , C07D241/12 , C07D241/08 , C07D239/74 , C07D239/34 , C07D239/26 , C07D237/08 , C07D231/12 , C07D215/14 , C07D213/55 , C07D211/98 , C07D211/22 , C07D207/08 , A61K38/26 , A61K31/53 , A61K31/505 , A61K31/501 , A61K31/50 , A61K31/4965 , A61K31/497 , A61K31/4709

CPC classification number: A61K31/551 , A61K31/402 , A61K31/4178 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/4468 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/4965 , A61K31/497 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/53 , A61K38/26 , C07D207/08 , C07D211/22 , C07D211/98 , C07D213/55 , C07D215/14 , C07D231/12 , C07D237/08 , C07D239/26 , C07D239/34 , C07D239/74 , C07D241/08 , C07D241/12 , C07D243/08 , C07D253/06 , C07D253/065 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/30 , C07D285/08 , C07D285/12 , C07D295/084 , C07D295/135 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04

Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

7.

发明授权
Substituted piperidines with antiparasitic activity 有权

公开(公告)号：US09688633B2

公开(公告)日：2017-06-27

申请号：US14774508

申请日：2014-03-14

Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

Inventor： Ignacio Aldana Moraza , Silvia Victoria Blair Trujillo , Eric Deharo , Giovanny Garavito , Adela Mendoza Lizaldez , Silvia Perez-Silanes

IPC: A61K31/445 , C07D211/04 , C07D211/70 , C07D409/06 , C07D211/98 , A61K31/4418 , A61K31/451 , A61K45/06 , C07D211/58

CPC classification number: C07D211/70 , A61K31/4418 , A61K31/451 , A61K45/06 , C07D211/58 , C07D211/98 , C07D409/06 , Y02A50/411

Abstract: The present invention relates to new arylaminoalcohol derivatives of formula (I), and to a method for the preparation of such compounds: I The invention also relates to the use of these compounds as medicaments, and in particular for the prevention and/or the treatment of parasitic diseases caused by apicomplexan parasites such as malaria and toxoplasmosis. Finally, the invention relates to pharmaceutical compositions containing such compounds of formula (I) as active principles.